Jaguar動物健康 JAGX 深 滬
已收盤 05-22 16:00:00 美东时间
2.91
-0.560
-16.14%
華盛通- 最 高3.25
- 今 開3.15
- 成交量 12.27万股
- 最 低 2.84
- 昨 收 3.47
- 總市值 175.51万
- 52周最高 152.60
- 市盈率 靜 --
- 換手率 20.34%
- 52周最低 2.53
- 委 比 66.92%
- 總股本 60.31万
- 歷史最高 87566062500.00
- 量 比 0.56
- 振 幅 11.82%
- 歷史最低 2.84
- 每 手 1
- 風險率 37.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Jaguar Health(JAGX)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Jaguar Health业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025财年第三季度合并净营收约310万美元，环比增长约4%（较2025财年第二季度的300万美元），同比持平（与2024财年第三季度的310万美元相等）。 **亏损情况：** - 归属于普通股股东的净亏损为950万美元，较2024财年第三季度的990万美元减少35.2万美元 - 运营亏损为730万美元，较2024财年第三季度的720万美元增加2.4万美元 - 非GAAP经常性EBITDA净亏损为890万美元，较2024财年第三季度的920
05-22 12:20
Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst consensus estimate of $(4.26) by 219.25 percent. This is a 97.67 percent increase over losses of $(584.45) per share
05-21 05:02
Jaguar Health's Napo Pharmaceuticals Announces That First Patient From Cohort Of Pediatric MVID Patients Has Entered The Active Treatment Only Single-Blind Extension To Study Safety And Efficacy
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind
05-19 21:11
Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy
Jaguar Health Inc. shares are climbing Wednesday after preliminary FDA talks on Breakthrough Therapy Designation for oral liquid crofelemer.
05-06 21:26
Jaguar Health Boosts Public Float to Regain Nasdaq Compliance
Jaguar Animal Health ( ($JAGX) ) has shared an update. On May 1, 2026, Jaguar H...
05-05 06:55
Jaguar Health Announces Acceptance Of Two Late Breaking Abstracts To Treat Pediatric Intestinal Failure From Microvillus Inclusion Disease And Short Bowel Syndrome
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual
04-24 20:32
Jaguar Health hosts investor webcast on Q4 2025 financials and company updates
Jaguar Health hosts investor webcast on Q4 2025 financials and company updates Jaguar Health schedules investor webcast on Q4 2025 financial results for April 10, 2026 at 8:30 a.m. Eastern. Webcast access: https://viavid.webcasts.com/starthere.jsp?ei=1754198&tp_key=0596f2aba1 . Replay link: https://
04-10 08:16
Jaguar Health reports Q4 results
Jaguar Health press release (JAGX): Q4 Revenue of $3.2M (-8.6% Y/Y). Net loss attributable to common shareholders increased by approximately $15.1 million, from $38.5 million in the year ended Decembe...
04-08 12:41
Jaguar Health FY25 net loss widens 37.6% to $54 million
Jaguar Health FY25 net loss widens 37.6% to $54 million Jaguar Health fiscal 2025 net loss widened 37.6% to $54 million. Revenue edged down 1.5% to $11.5 million. Operating loss expanded 48.9% to $45.9 million. Cash totaled $968,000 at Dec. 31, 2025, while stockholders’ deficit was $18.7 million. Ja
04-07 18:11
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
